Fludarabine CAS 21679-14-1

Fludarabine (NSC 118218), with the chemical name 9H-Purin-6-amine, F-Ara-A
Fludarabinum, monosodium salt, and CAS number 21679-14-1, is a synthetic purine nucleoside analog that has gained prominence as an antineoplastic and immunosuppressive agent. It is a vital component in the field of oncology and hematology, used primarily for the treatment of various hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Fludarabine exerts its therapeutic effects by interfering with DNA synthesis and repair processes, disrupting cell division, and inducing apoptosis in rapidly dividing cells. This compound's unique mechanism of action and clinical significance make it an essential tool in the arsenal of treatments for certain hematological disorders.

❶ Purine Nucleoside Analog: Fludarabine is a synthetic analog of the purine nucleoside adenosine. This structural resemblance allows it to be incorporated into DNA and RNA during replication and transcription, disrupting normal cellular processes.

❷ Selective Action: Fludarabine is more readily taken up by malignant cells, particularly lymphocytes, compared to normal cells. This selective uptake contributes to its effectiveness against certain hematologic cancers like chronic lymphocytic leukemia (CLL).

❸ Immunosuppressive Properties: Besides its antineoplastic effects, fludarabine also exhibits immunosuppressive properties. This makes it valuable for conditions like CLL, where excessive immune activity contributes to disease progression.

❹ Inhibition of DNA Repair: Fludarabine interferes with DNA repair enzymes, leading to accumulation of DNA strand breaks and impairing DNA synthesis. This mechanism contributes to its cytotoxic effects on rapidly dividing cancer cells.

❺ Resistance Minimization: Fludarabine's structural modification from the naturally occurring nucleoside reduces susceptibility to degradation by adenosine deaminase, an enzyme that can impact the effectiveness of other nucleoside analogs.

❻ Route of Administration: Fludarabine is typically administered intravenously, allowing for controlled dosing and efficient delivery to target cells. 

❼ Combination Therapy: Fludarabine is often used in combination with other chemotherapeutic agents or monoclonal antibodies to enhance treatment efficacy in hematologic malignancies.
❽ Dose Adjustment: Fludarabine dosages may need to be adjusted based on factors such as renal function and patient tolerance to minimize potential side effects. 

❾ Clinical Versatility: Beyond CLL, fludarabine has demonstrated effectiveness in treating other hematologic disorders like acute myeloid leukemia and non-Hodgkin lymphomas. 

❿ Adverse Effects: Common side effects of fludarabine therapy include myelosuppression, immunosuppression, and potential risk of opportunistic infections.